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Abstract
 
Multiple sclerosis (MS) is considered to be an autoimmune disease of the central nervous sys-
tem (CNS) that in many patients first presents clinically as optic neuritis. The relationship of
optic neuritis to MS is not well understood. We have generated novel T cell receptor (TCR)
transgenic mice specific for myelin oligodendrocyte glycoprotein (MOG). MOG-specific
transgenic T cells are not deleted nor tolerized and are functionally competent. A large propor-
tion (
 
 
 
30%) of MOG-specific TCR transgenic mice spontaneously develop isolated optic
neuritis without any clinical nor histological evidence of experimental autoimmune encephalo-
myelitis (EAE). Optic neuritis without EAE could also be induced in these mice by sensitiza-
tion with suboptimal doses of MOG. The predilection of these mice to develop optic neuritis
is associated with higher expression of MOG in the optic nerve than in the spinal cord. These
results demonstrate that clinical manifestations of CNS autoimmune disease will vary depend-
ing on the identity of the target autoantigen and that MOG-specific T cell responses are in-
volved in the genesis of isolated optic neuritis.
Key words: MOG • experimental autoimmune encephalomyelitis • multiple sclerosis • 
autoimmunity of CNS • disease model
 
Introduction
 
Multiple sclerosis (MS)
 
* 
 
is considered to be an autoimmune
disease in which central nervous system (CNS) myelin is
the target of an immune attack resulting in inflammation
and demyelination in the CNS. It has become increasingly
recognized that MS may not be a single disease entity, but
instead involves different immunopathological processes
manifested as different clinical phenotypes that include re-
lapsing-remitting and progressive forms (1). The first clini-
cal presentation in a significant proportion of MS patients is
optic neuritis, which is then followed by the development
 
of relapsing-remitting MS (2, 3). The underlying immuno-
logical basis for different clinical forms of MS and its associ-
ation with optic neuritis are not well defined. In particular,
whether optic neuritis is a different disease entity that pre-
disposes patients to develop subsequent involvement of
CNS myelin, or whether it is part of a continuum of dis-
ease process that initially involves myelin in the optic
nerve and is then followed by involvement of brain and
spinal cord white matter, is not well understood. Whether
an autoimmune response to a specific myelin antigen re-
sults in the preferential induction of optic neuritis has not
been addressed.
 
Experimental autoimmune encephalomyelitis (EAE) serves
as an animal model that recapitulates many features of MS.
It can be induced by immunization of susceptible animals
with a number of myelin antigens including myelin basic
protein (MBP; 4), proteolipid protein (PLP; 5–7), and
myelin oligodendrocyte glycoprotein (MOG; 8). MOG,
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77 Avenue Louis Pasteur, Boston, MA 02115. Phone: 617-525-5350;
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*
 
Abbreviations used in this paper:
 
 CNS, central nervous system; EAE, ex-
perimental autoimmune encephalomyelitis; MBP, myelin basic protein;
MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis;
PLP, proteolipid protein; TBS, Tris-buffered saline.T
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although a minor component of the myelin sheath, has
been shown to be a potent encephalitogenic protein that
induces EAE in many strains and species of experimental
animals (9–13) and is also implicated in the pathogenesis of
MS (14, 15). In EAE, the identity of the target autoantigen
at least in part determines the disease phenotype and pattern
of lesion distribution in the CNS. For example, immune
responses to MBP or PLP induces lesions located predomi-
nantly in the spinal cord whereas immunization with MOG
generates optic nerve and spinal cord lesions (16).
Optic nerve lesions have been reported in some forms of
EAE, but have always been associated with the presence of
inflammation and demyelination of the brain and spinal
cord (17–21). In these EAE models, development of optic
neuritis required active immunization and it is unclear
whether optic neuritis preceded or followed the develop-
ment of EAE. Several different TCR transgenic mice have
been generated that express TCRs specific for MBP or PLP
peptides including one that expresses TCRs specific for hu-
man MBP in the context of HLA-DR2 (22–25). These
transgenic mice develop spontaneous EAE with different
frequencies, but none have been reported to develop spon-
taneous isolated optic neuritis. In this report, we describe
the generation of a TCR transgenic mouse (2D2) specific
for the MOG 35–55 peptide on the C57Bl/6 background.
A large proportion of mice develop spontaneous optic neu-
ritis without evidence of clinical nor histological EAE, sug-
gesting the role for MOG-specific T cell responses in the
induction of optic neuritis.
 
Materials and Methods
 
Antigens.
 
The peptide MOG 35–55 (MEVGWYRSPFSRV-
VHLYRNGK) and OVA 323–336 (ISQAVHAAHAEINE) were
synthesized by D. Teplow at the Biopolymer Facility, Center for
Neurologic Diseases, Boston, MA. The extracellular domain of
murine MOG was produced as an HIS-tagged recombinant pro-
tein and was provided by Genetics Institute.
 
Generation of the 2D2 Clone.
 
C57Bl/6 mice were immu-
nized with 100 
 
 
 
g MOG 35–55 peptide emulsified in CFA. 10 d
later, lymph nodes from immunized mice were collected and
stimulated with 20 
 
 
 
g/ml peptide. These T cells were restimu-
lated three times in vitro with the same amount of peptide and
cloned by limiting dilution. We analyzed TCR expression on the
surface of these T cell clones using various commercially available
anti-TCRV
 
  
 
and anti-TCRV
 
  
 
antibodies. The 2D2 clone was
selected for generation of TCR transgenic mice because it
expressed a TCR combination (V
 
 
 
3.2 and V
 
 
 
11) for which spe-
cific antibodies are available.
 
Generation of TCR Transgenic Mice.
 
The rearranged TCR
 
 
 
and TCR
 
  
 
chains from 2D2 genomic DNA were analyzed by se-
quencing. The amino acid sequence of the CDR3 regions is as
follows: TCR
 
 
 
, VYF CALRSY NFG; TCR
 
 
 
, CASS LDCG
ANP. The V
 
 
 
3.2J
 
 
 
18 and V
 
 
 
11DJ
 
 
 
1.1 regions of 2D2 TCR
were amplified by PCR from genomic DNA with specific prim-
ers. PCR products were cloned into TCR expression cassettes
(26). Linearized TCR containing plasmids were injected directly
into the pronuclei of fertilized C57Bl/6 oocytes. Transgenic
founders were identified by PCR using specific primers for 2D2
V
 
 
 
-J
 
  
 
and V
 
 
 
-J
 
  
 
regions. Transgenic founder mice were bred
 
with C57Bl/6 mice (The Jackson Laboratory). Alternatively,
2D2 TCR transgenic mice were bred with C57Bl/6 RAG-1
 
 
 
/
 
 
 
(The Jackson Laboratory) and then intercrossed to generate 2D2
TCR transgenic RAG-1
 
 
 
/
 
  
 
mice. Routine screening to identify
the transgenic mice was performed by FACS
 
® 
 
analysis from blood
using specific antibodies to V
 
 
 
11 or V
 
 
 
3.2. For phenotyping, the
blood was always drawn from the tail and not from the eyes of
these animals. Mice were housed in a specific pathogen-free/viral
antibody-free animal facility at the Harvard Institutes of Medi-
cine. All breeding and experiments were performed in accor-
dance with the guidelines of the committee on Animals of Har-
vard Medical School.
 
Flow Cytometry.
 
Single cell suspension from thymi and
spleens were prepared and cells were stained with FITC, PE, or
tricolor-conjugated antibodies for 30 min at 4
 
 
 
C (anti-TCR
 
 
 
,
anti-TCRV
 
 
 
3.2, anti-TCRV
 
 
 
11, and anti-CD8 antibodies; BD
Biosciences and anti-CD4 antibody; Caltag Laboratories). After
washing they were analyzed on a FACS
 
® 
 
sort flow cytometer
(Becton Dickinson).
 
Proliferation Assays and Cytokine ELISA.
 
Cells were grown in
RPMI 10% FCS supplemented with 5 
 
  
 
10
 
 
 
5 
 
M 
 
 
 
-mercaptoeth-
anol, 
 
l
 
-glutamine, gentamicin sulfate, and 100 U/
 
 
 
g penicillin/
streptomycin. For proliferation assays, splenocytes (5 
 
  
 
10
 
5 
 
cells/
well) were cultured for 72 h in 96-well plates in the presence of
the indicated concentration of peptide. Cells were pulsed with 1
 
 
 
Ci [
 
3
 
H]thymidine for the last 16 h of incubation and mean thy-
midine incorporation in triplicate wells was measured using a 
 
 
 
counter (model LS 5000; Beckman Coulter). The concentration
of cytokines (IFN-
 
 
 
, IL-10, IL-5, and IL-4) was determined in
culture supernatants by cytokine ELISA according to the manu-
facturer’s guidelines (BD Biosciences).
 
Induction and Assessment of EAE and Optic Neuritis.
 
Mice
were examined routinely for the development of spontaneous
disease. Three different protocols were used to induce disease in
transgenic and nontransgenic mice. Mice were immunized with
100 
 
 
 
g MOG 35–55 emulsified in CFA (CFA supplemented
with 400 
 
 
 
g/ml 
 
Mycobacterium tuberculosis
 
) and injected intrave-
nously on days 0 and 2 with 150 ng pertussis toxin. In a second
protocol, mice received only injections of pertussis toxin. In a
third protocol, mice were immunized with either 10 or 100 
 
 
 
g
MOG 35–55 peptide emulsified in CFA without any pertussis
toxin. Clinical assessment of EAE was performed daily according
to the following criteria: 0, no disease; 1, decreased tail tone; 2,
hind limb weakness or partial paralysis; 3, complete hind limb pa-
ralysis; 4, front and hind limb paralysis; 5, moribund state.
Mice developing spontaneous optic neuritis presented eyelid
redness and swelling associated with tearing. In some cases these
signs evolved to a partial or complete atrophy of the eye.
 
Western Blot Analysis.
 
Optic nerve and spinal cord homoge-
nates from adult female C57Bl/6 mice were prepared in PBS in
the presence of a protease inhibitor cocktail (Sigma-Aldrich) and
20 U/
 
 
 
l DNase. Protein concentrations were measured photo-
metrically by the Bradford assay. Equal amounts of protein were
loaded on 15% SDS-polyacrylamide gels and after SDS-PAGE
they were blotted on a nitrocellulose membrane (Amersham Bio-
sciences). After blocking with Tris-buffered saline (TBS)/5%
milk powder, the membrane was incubated with a MOG-specific
rabbit antiserum (27) overnight at 4
 
 
 
C. The membrane was then
washed extensively and incubated with a peroxidase-conjugated
goat anti–rabbit IgG (Dianova). The blot was developed using an
enhanced chemiluminescent system (Amersham Biosciences) and
the signal was detected and quantified using a computer-linked
CCD-Camera (LAS-1000; Fujifilm). Antibodies were thenT
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stripped from the membrane by washing in TBS followed by in-
cubation for 30 min at 50
 
 
 
C in 62.5 mM Tris/HCl, pH 6.7, con-
taining 100 mM 
 
 
 
-mercaptoethanol and 2% SDS. Membranes
were then washed with TBS and blocked with TBS/5% milk
powder before being reprobed with an immunopurified rabbit
anti–PLP antibody (28) and assayed as described above.
 
Histology.
 
Animals were killed at the termination of the in-
duced disease or after at least 2 wk of spontaneous EAE or optic
neuritis. Brains, spinal cords, eyes, and associated optic nerves
were removed and fixed in 10% formalin. Paraffin-embedded
sections were stained with hematoxylin and eosin, Luxol fast blue
stains, and by Bielschowsky preparation for light microscopy. Im-
munohistochemistry on cryosections from selected transgenic and
nontransgenic mice was performed using antibodies to CD4 and
TCRV
 
 
 
11 as previously described (24).
 
Results
 
Selection of T Cells in MOG-specific TCR Transgenic
Mice.
 
We derived a CD4
 
  
 
MOG 35–55–specific T cell
clone called 2D2 from C57Bl/6 mice. The 2D2 clone ex-
pressed a TCR composed of V
 
 
 
3.2 and V
 
 
 
11. The rear-
ranged TCR
 
  
 
and TCR
 
  
 
chains of this clone were cloned
in expression cassettes and injected into C57Bl/6 oocytes
(H-2
 
b
 
) to generate 2D2 TCR transgenic mice.
There was no difference in cellularity in the thymi and
spleens between the 2D2 TCR transgenic mice and the
nontransgenic littermate control mice. CD4, CD8, and
specific TCR expression were analyzed on cells isolated
from thymi and spleens from 2D2 TCR transgenic mice
and nontransgenic control littermates. As shown in Fig. 1
A, the ratio between CD4
 
  
 
and CD8
 
  
 
single positive thy-
mocytes is biased toward the CD4 compartment in 2D2
TCR transgenic mice compared with nontransgenic litter-
mates. In addition, the majority of thymocytes in 2D2
TCR transgenic mice expressed high and intermediate lev-
els of TCR indicating efficient positive selection of trans-
 
genic T cells (Fig. 1 B). Analysis of splenocytes also re-
vealed a skewing toward CD4
 
  
 
cells in the 2D2 TCR
transgenic mice compared with the nontransgenic litter-
mates (Fig. 1 C). In addition, the majority of CD4
 
  
 
T cells
from these 2D2 transgenic mice expressed the transgenic
TCR defined by V
 
 
 
3.2 and V
 
 
 
11 (Fig. 1 C). The analysis
of 2D2 TCR transgenic mice on RAG-1
 
 
 
/
 
  
 
background
showed that transgenic V
 
 
 
3.2
 
  
 
V
 
 
 
11
 
  
 
T cells are positively
selected in the thymus and do not undergo detectable dele-
tion. Transgenic V
 
 
 
3.2
 
  
 
V
 
 
 
11
 
  
 
T cells represented 
 
 
 
98%
of CD3
 
  
 
T cells (not depicted).
 
Transgenic T Cells from 2D2 TCR Transgenic Mice Prolifer-
ate in Response to MOG 35–55 Peptide and MOG Protein.
 
To determine if the T cells were specific and responsive to
MOG antigen in the peripheral lymphoid organs, we tested
the proliferative response of spleen cells with the peptide
MOG 35–55 and whole MOG protein. As shown in Fig.
2, A and B, spleen cells from naive 2D2 TCR transgenic
mice with no sign of CNS autoimmune disease show a
strong proliferative response to the peptide MOG 35–55
and to the MOG protein. However, they do not proliferate
to a control peptide OVA 323–336. We also tested the
production of various cytokines (IFN-
 
 
 
, IL-4, IL-10, and
IL-5) from these transgenic T cells in response to the en-
cephalitogenic peptide. Spleen cells from unimmunized
2D2 TCR transgenic mice produce high levels of IFN-
 
 
 
but no other cytokines were detected in the supernatant in
response to the peptide MOG 35–55 (Fig. 2 C). The
source of the IFN-
 
  
 
appears to be from memory/primed T
cells because production of IFN-
 
  
 
was considerably re-
duced when sorted naive CD4
 
  
 
CD62L
 
high 
 
transgenic T
cells were activated in vitro with the MOG 35–55 peptide
(unpublished data). Memory/primed transgenic T cells
(V
 
 
 
3.2
 
  
 
CD4
 
  
 
CD62L
 
low
 
) represent 
 
 
 
10% of the CD4
 
 
 
transgenic T cell population. This percentage increases as
the animals age. These results show that T cells from 2D2
Figure 1. T cell populations in 2D2 MOG-specific TCR transgenic mice. Thymocytes (A and B) or splenocytes (C) from 6–8-wk-old 2D2 TCR
transgenic mice (2D2 Tg) or nontransgenic littermates (NT) were stained with antibodies to CD4, CD8, TCR , V 11, and V 3.2 and cells were ana-
lyzed by flow cytometry. The dot plots show two-color flow cytometry analysis of the thymocytes or splenocytes. B contains histograms showing TCR
expression on total thymocytes.T
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TCR transgenic mice are able to respond to MOG antigen
(peptide and protein) and that they are not tolerized in
vivo. Furthermore, the data suggest that transgenic T cells
have a tendency to develop into a Th1 phenotype.
2D2 TCR Transgenic Mice Develop Spontaneous Optic Neu-
ritis. We evaluated the development of spontaneous dis-
ease in 72 2D2 MOG-specific TCR transgenic mice
housed under specific pathogen-free/viral antibody-free
conditions. The incidence of spontaneous EAE in these
mice is low in that only 4% (3/72) of transgenic mice de-
veloped spontaneous EAE (Table I, group A). In the 2D2
TCR transgenic mice that developed spontaneous disease,
the first clinical signs of EAE were a limp tail followed by
hind limb paralysis. These signs appeared between 2.5 and
5 mo of age. Transgenic mice with clinical EAE had typical
inflammatory/demyelinating lesions and associated edema
in their brains and spinal cords (Table I, group A, and Fig.
3 A). CD4  and TCRV 11  infiltrating T cells were iden-
tified by immunohistochemistry in the lesions (Fig. 3, B
and C). Histopathological examination of optic nerve from
these mice also showed inflammatory/demyelinating le-
sions of optic neuritis (Fig. 3 E).
69 of the 72 mice examined did not show any signs of
clinical EAE (Table I, group B). During routine care and
evaluation of these TCR transgenic mice, we observed the
development of superficial inflammation around the eye-
lids, eyelid swelling, and tearing. These lesions were unilat-
eral and only seen in 2D2 TCR transgenic mice and not in
control littermates. The signs were often associated with a
progressive atrophy of the eye. Therefore, we randomly se-
lected 37 TCR transgenic mice in this group of mice that
did not develop EAE and monitored them closely for the
signs of ocular disease. Surprisingly, a significant proportion
(35%) of these otherwise healthy TCR transgenic animals
developed these ocular abnormalities in the absence of any
sign of spontaneous EAE when observed for periods of up
to 1 yr (Table I, group B).
To determine the cause of these signs, we performed a
blinded detailed histological analysis of the brain, spinal
cord, eyes, and associated optic nerves collected from 2D2
TCR transgenic mice (n   15) chosen at random from
group B. Consistent with the absence of clinical signs of
EAE, histopathological analysis of brains and spinal cords
from these mice demonstrated no or very few lesions in
these tissues. However, 7 of the 15 (47%) TCR transgenic
mice with no clinical evidence of EAE had histological
evidence of optic neuritis without any detectable lesions
in the brain and spinal cord (Table I, group B, and Fig.
3 D). Histological examination of optic nerves from
these animals revealed inflammatory/demyelinating lesions
Figure 2. Response of transgenic T cells to MOG 35–55 and MOG
protein. Splenocytes from unimmunized mice were cultured with indi-
cated concentrations of MOG 35–55 peptide (A) or recombinant protein
MOG (B). T cell proliferation was determined by [3H]thymidine incor-
poration in triplicate wells in a 72-h proliferation assay. The mean cpm’s
in the presence of 50  g/ml OVA 323–336 control peptide were 12,401
for TCR transgenic mice and 14,278 for the control littermates. Spleno-
cytes produce IFN-  in response to indicated concentrations of peptide
MOG 35–55 (C). IFN-  was measured on supernatants harvested 48 h
after activation by ELISA. 2D2 Tg, 2D2 transgenic; NT, nontransgenic.
Table I. Spontaneous Optic Neuritis in 2D2 TCR
Transgenic Mice
Clinical Histological
EAE
Optic
neuritis EAE
Optic
neuritis
Group A
Mice with EAE
4%
(n   72)a ND
100%
(n   3)
100%
(n   3)
Group B
Mice without EAE
0%
(n   69)
35%
(n   37)b
0%
(n   15)c
47%
(n   15)c
2D2 TCR transgenic mice were monitored for signs of EAE and optic
neuritis.
a72 TCR transgenic mice were monitored for EAE. Based on clinical
signs of EAE, two groups of mice were distinguished. Group A repre-
sents mice that developed spontaneous clinical EAE (n   3) and group
B represents mice that never showed any signs of spontaneous EAE
(n   69).
bAmong the 69 transgenic mice that did not develop EAE, 37 were ex-
amined closely for up to 1 yr for clinical signs of optic neuritis as de-
scribed in Materials and Methods.
cThe eyes, optic nerves, brain, and spinal cord from 15 TCR transgenic
mice with or without clinical signs of optic neuritis were analyzed by
histology. Mice were killed at 6.3   2.5 mo of age. Most mice (67%)
with clinical optic neuritis had histological lesions in the optic nerve.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
1077 Bettelli et al.
equivalent to those seen in the optic nerves of mice with
clinical EAE. These lesions consisted of subpial and endo-
neurial mononuclear cell infiltrates with active demyelina-
tion indicated by the presence of foamy macrophages (Fig.
3, E and H). Myelin stains demonstrated patchy and dif-
fuse plaque-like patterns of myelin loss (Fig. 3 F) and there
were varying degrees of axonal injury and loss (Fig. 3 G).
Adjacent oculomotor nerves containing peripheral ner-
vous system myelin, which lacks MOG, were free of le-
sions and the eyes showed normal histology. Some mice
with optic neuritis also showed nonspecific chronic in-
flammation in adjacent skin and periorbital tissues, possi-
bly secondary to local trauma. Histological findings corre-
lated with clinical observations because 67% of TCR
transgenic mice with superficial eye lesions also had optic
neuritis. The small size of these nerves and the patchy
nature of lesions may have precluded histologic demon-
stration of optic neuritis in some mice with clinical op-
tic neuritis. These observations are specific to the 2D2
MOG-specific TCR transgenic mice because we did not
observe any clinical ocular abnormalities or lesions in the
brains, spinal cords, or optic nerve of nontransgenic litter-
mates (not depicted).
Suboptimal Immunization Regimen Triggers Optic Neuritis
but not EAE. To understand the mechanisms responsible
for induction of optic neuritis in the 2D2 transgenic mice
and the relationship of optic neuritis to EAE, we studied
the effects of different immunization protocols on the de-
velopment of EAE versus optic neuritis in the mice. First,
we determined whether EAE could be induced in the
MOG TCR transgenic mice by the standard immuniza-
tion protocol that included MOG 35–55 peptide emulsi-
fied in CFA and the injection of pertussis toxin. As shown
in Fig. 4 A and Table II, 2D2 TCR transgenic mice devel-
oped more severe EAE when immunized with the full
regimen compared with the nontransgenic littermates.
This was associated with a higher mortality, accelerated
onset, and more numerous CNS inflammatory foci. Next,
we investigated whether by reducing the immunogenicity
of the emulsion we would be able to induce optic neuritis
in the absence of EAE. First, we injected 2D2 MOG-spe-
cific TCR transgenic mice with pertussis toxin alone.
With this regimen, 39% of the TCR transgenic mice de-
veloped typical clinical EAE and 56% developed histologi-
cal EAE. None of the negative littermates showed any
signs of disease (Fig. 4 B and Table II). In this and the pre-
ceding experiment, EAE was associated with the develop-
ment of optic neuritis. 80% of the mice immunized with
the standard regimen and 50% of the animals injected with
pertussis toxin developed EAE associated with optic neuri-
tis (Fig. 5).
Next, we immunized the mice with two different doses
of MOG 35–55 peptide emulsified in CFA without any
additional pertussis toxin. With this regimen, none of the
transgenic mice developed clinical signs of EAE (Table II).
Consistent with this observation, the brains and spinal
Figure 3. Histological analysis of
CNS tissues from 2D2 TCR trans-
genic mice. (A) Typical meningeal
and parenchymal mononuclear cell
infiltrates associated with demyelina-
tion and edema in spinal cord of
mouse with optic neuritis and clini-
cal EAE. A spinal nerve root (pe-
ripheral nerve myelin) as indicated
by an arrow is spared. Luxol fast blue
and hematoxylin and eosin stain,
 206. (B) CD4  cells (arrows) infil-
trate cerebellar white matter. Cryo-
section with mAb GK1.5 immuno-
peroxidase stain,  308. (C) Similar
numbers of cells in a section adjacent
to B stain for TCR V 11. Cryosec-
tion with mAb RR3–15 immuno-
peroxidase stain,  308. (D) Intact
spinal cord from mouse with optic
neuritis but no clinical nor histologic
EAE. Luxol fast blue and hematoxy-
lin and eosin stain,  206. (E) Longi-
tudinal section of optic nerve from
mouse with optic neuritis and EAE.
Portions of an uninvolved oculomo-
tor nerve (peripheral nerve myelin)
are in the lower portion of the field.
Hematoxylin and eosin stain,  308.
(F) Adjacent section to E demonstrating demyelination (pale area in left side of field) in optic neuritis. Blue staining on right side and in oculomotor
nerve indicates preserved myelin. Inset: diffuse vacuolation of optic nerve myelin associated with few inflammatory cells. Klüver-Barrera stain,  308. (G)
Adjacent section to E and F showing intact silver-positive axons (arrows) in oculomotor nerve. Axons are lost in the optic nerve (center). Bielschowsky
preparation,  308. (H) Subpial and diffuse endoneurial mononuclear cell infiltrate in cross section of optic nerve of a transgenic mouse without EAE. In-
set: higher power of an endoneurial mononuclear cell infiltrate. Hematoxylin and eosin stain,  206; inset,  308.T
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cords of peptide-immunized 2D2 TCR transgenic mice
showed minimal or no inflammatory foci (Table II). Inter-
estingly, immunization with either dose of MOG35–55 in
CFA induced histological optic neuritis at a very high fre-
quency (Fig. 5). 55 and 78% of mice immunized with 100
and 10  g MOG35–55 peptide, respectively, had lesions in
the optic nerves. These results show that activation of
transgenic T cells under milder conditions is sufficient to
trigger optic neuritis while sparing the remainder of the
CNS. This provides a reproducible method for induction
of optic neuritis in MOG-specific TCR transgenic mice,
without concomitant induction of EAE.
MOG Is More Expressed in the Optic Nerve than in the Spi-
nal Cord. The predilection of 2D2 TCR transgenic mice
to develop optic neuritis is apparently antigen specific be-
cause isolated optic neuritis was not reported in MBP- and
PLP-specific TCR transgenic mice (22–25). To investigate
whether this was due to differential expression of MOG in
the optic nerve and spinal cord, we compared the levels of
MOG and PLP in these tissues by semiquantitative West-
Figure 4. Induced EAE in 2D2 TCR transgenic mice. 2D2 TCR
transgenic mice and nontransgenic littermates were immunized with
MOG 35–55 peptide emulsified in CFA and injected with pertussis toxin
(A) or injected with pertussis toxin only (B) and observed for the devel-
opment of EAE over time. The data are presented as the mean disease
score in each group during the course of observation. 2D2 Tg, 2D2 trans-
genic; NT, nontransgenic.
Table II. EAE Induced in 2D2 TCR Transgenic Mice and Negative Control Littermates
Clinical EAE Histological EAE
Treatmenta Incidence Mortality Mean day of onsetb Mean maximal scorec Incidenced Mean number of focie
MOG35–55   PT Tg 9/10 (90%) 4/10 (40%) 11.9   1.2 4.0   0.3 8/10 (80%) 170.9   38.3
NT 9/11 (82%) 0/11 (0%) 14.5   2.2 2.6   0.4 8/10 (80%) 78.9   24.9
PT alone Tg 9/23 (39%) 3/23 (13%) 14.1   2.1 3.8   0.3 9/16 (56%) 39.3   11.4
NT 0/6 (0%) 0/6 (0%) NA NA 1/5 (20%) 5.5   4.1
MOG35–55 100  g Tg 0/9 (0%) 0/9 (0%) NA NA 0/9 (0%) 2.4   0.9
NT 0/9 (0%) 0/9 (0%) NA NA 1/5 (20%) 5.0   2.9
MOG35–55 10  g Tg 0/9 (0%) 0/9 (0%) NA NA 0/9 (0%) 2.3   1.0
NT 1/9 (11%) 0/9 (0%) 23   02     0 4/10 (40%) 16.9   7.2
a2D2 TCR transgenic (Tg) and nontransgenic (NT) littermates were immunized by various regimens including MOG35–55 peptide in CFA and
pertussis toxin (PT), PT alone, or MOG peptide alone in CFA. The animals were then monitored for signs of EAE.
bData are presented as mean   SE.
cData are presented as mean maximal clinical scores for the animals showing clinical disease.
dMice with  10 lesions in brain and spinal cord were considered positive.
eData are presented as mean number of meningeal and parenchymal inflammatory lesions in brain and spinal cord.
Figure 5. Suboptimal immunization protocols trigger optic neuritis but
not EAE in 2D2 TCR transgenic mice. 2D2 TCR transgenic mice were
immunized with 100  g MOG 35–55 peptide emulsified in CFA and in-
jected with pertussis toxin, immunized with 10 or 100  g of the MOG
35–55 peptide alone, or injected with pertussis toxin only. The propor-
tion of mice developing EAE or optic neuritis was evaluated by histolog-
ical analysis of brains, spinal cords, and optic nerves. The number of mice
developing EAE or optic neuritis in each group is indicated in parentheses
on the right side of the histogram bar.T
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ern blotting. Spinal cord was analyzed because lesions in
mice with EAE are consistently found in the spinal cord.
This approach revealed significantly higher levels of MOG
in the optic nerve than the spinal cord (Fig. 6, left). The
signal obtained for MOG was 51% higher in the optic
nerve than in the spinal cord (P   0.00596). In contrast,
PLP levels/ g total protein were very similar in the two
tissues (Fig. 6, right). These results suggest that the devel-
opment of spontaneous optic neuritis in these MOG-spe-
cific TCR transgenic mice might be related to an increased
autoantigen expression in the optic nerves.
Discussion
In this report, we describe the generation of a new
MOG 35–55–specific TCR transgenic mouse on the
C57Bl/6 background. In these TCR transgenic mice,
CD4  T cells appear to develop normally and do not un-
dergo central nor peripheral tolerance. Although MOG
protein expression has not been detected in the thymus
(29), the presence of MOG mRNA has been reported in a
subpopulation of medullary thymic epithelial cells (30).
Our results would suggest that the MOG protein may not
be translated in thymic cells or that the expression level is
not sufficient to induce tolerance of MOG-specific T cells
to this autoantigen.
We show that a large proportion of MOG-specific
TCR transgenic mice develop spontaneous optic neuritis
without any clinical nor histological sign of EAE. These
mice also develop EAE when immunized with the full im-
munization regimen of encephalitogenic peptide plus per-
tussis toxin but developed optic neuritis without EAE
when immunized under suboptimal immunization condi-
tions (encephalitogenic peptide emulsified in CFA but no
pertussis toxin). Thus, these mice not only provide a
model to investigate the role and nature of the MOG-spe-
cific self-reactive repertoire, but also to study optic neuritis
and its relationship to the development of autoimmunity
in the CNS.
Different forms of clinical EAE can be induced in exper-
imental animals depending on the genetic background and
immunizing myelin antigen. The clinical phenotypes re-
ported in EAE range from monophasic (in Lewis rats with
MBP immunization) to relapsing-remitting (in SJL mice
immunized with PLP or dark agouti rats immunized with
MOG; 5, 31) or chronic/chronic progressive forms (in
C57Bl/6 or NOD mice immunized with MOG; 8). These
disease forms in EAE correspond to various clinical pheno-
types observed in MS. Optic neuritis is a common initial
sign in 30–60% of patients with MS (2, 32). Optic neuritis
is observed in EAE as well but is often associated with in-
flammation in the brain or spinal cord after immunization
with myelin antigens (17–21). In contrast, our MOG TCR
transgenic mice provide an experimental model in which
spontaneous optic neuritis develops without any clinical
nor histological evidence of EAE. This situation is compa-
rable to what occurs in many MS patients before the in-
volvement of the brain or spinal cord and the onset of re-
lapsing-remitting disease.
Several transgenic mice with TCRs specific for other
myelin antigens have been generated. Although MOG-
specific TCR transgenic mice develop spontaneous optic
neuritis, none of the MBP- nor PLP-specific TCR trans-
genic mice have been reported to develop spontaneous op-
tic neuritis (22–25). Several hypotheses can explain this dif-
ference. First, the differences might be related to the
genetic background (non-MHC) of the animals. Previous
work has shown that the pathology of EAE and incidence
of optic neuritis differ in MOG-immunized BN and
LEW.1N rats which express identical MHC but different
non-MHC background genes (33).
Accumulating evidence also suggest that immune re-
sponses for different target antigens might induce different
types of immunopathology and disease signs in EAE (34,
35). For example, immunization of rats with MOG in-
duces a spectrum of CNS pathology (33). The majority of
animals ( 80%) developed lesions involving the spinal
cord and the optic nerve similar to human neuromyelitis
optica. However, only a limited number of MOG-immu-
nized rats developed optic neuritis in the absence of lesions
in the brain and spinal cord (33). These data in rats and
our finding of spontaneous optic neuritis in the MOG-
specific TCR transgenic mice suggest that anti-MOG au-
toimmune responses may have a role in the induction of
human optic neuritis.
The low incidence of spontaneous EAE compared with
the high incidence of optic neuritis in the MOG-specific
TCR transgenic mice suggest that infiltration by MOG-
specific T cells is achieved more readily in the optic nerve
than in the brain and spinal cord. This might relate to dif-
ferences in the nature of blood-tissue barriers between op-
tic nerve and the CNS proper, to the level/proportion of
activated myelin-reactive T cells that are required for the
induction of optic neuritis compared with EAE, local dif-
ferences in antigen concentration, or a combination of
Figure 6. MOG is more expressed in the optic nerve than in the spinal
cord. Optic nerves and spinal cords homogenates were assayed by SDS-
PAGE for MOG and PLP expression using respective-specific antibodies.
Histograms represent mean relative expression of MOG and PLP in optic
nerves and spinal cords pooled from five C57Bl/6 mice and assayed in
quadruplicates. The data presented were obtained at a protein loading of
16.6  g/well and are representative of multiple analysis of three indepen-
dent experiments. NS, not significant.T
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these factors. Our results suggest that the predilection of
2D2 transgenic mice to develop spontaneous optic neuritis
may in part explained by higher expression of MOG in the
optic nerve than in the spinal cord. These differences in
MOG concentration correlate with its localization in the
myelin sheath. MOG is expressed in the outermost surface
of the oligodendrocyte myelin sheath. In the optic nerve,
where the volume to surface ratio of the myelin is low,
MOG expression is increased relative to protein such as
PLP, which is concentrated in the compact myelin. Effects
of differential antigen concentration could become clini-
cally significant in the context of suboptimal T cell re-
sponses. Indeed, our data show that a low grade activation
by a suboptimal immunization regimen of MOG-specific
transgenic T cells is sufficient to result in the development
of optic neuritis without EAE. By contrast, with the full
immunization regimen (peptide plus pertussis toxin), the
transgenic mice develop EAE in addition to optic neuritis.
This suggests that the progression of optic neuritis to full-
fledged EAE is a continuum in the development of CNS
pathology, with a low frequency of activated autoreactive
T cells favoring the development of optic neuritis and a
higher frequency of activated MOG-reactive T cells favor-
ing development of full-blown EAE. Similarly, this might
also be one of the reasons why many MS patients initially
develop optic neuritis, presumably because they only have
a low frequency of activated T cells specific for MOG.
They may later develop relapsing-remitting disease because
of epitope spreading (36). Epitope spreading after this ini-
tial insult may then be responsible for the subsequent de-
velopment of lesions in the brain and spinal cord and pro-
gression of clinical disease.
In conclusion, 2D2 MOG-specific TCR transgenic mice
will not only allow us to study the autoimmune response to
an important myelin antigen, but also provide a unique
model to study spontaneous optic neuritis and its relation-
ship to the development of EAE. The results with TCR
transgenic mice demonstrate that clinical manifestations of
CNS-specific autoimmune disease will vary depending on
the involvement of the target autoantigen.
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